Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 17/20 | 0.62 |
| ▸ | AR | P10275 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096628 | 0.81 | TSHR (0.64) | PARP1ARLMNACYP3A4CYP2C9 | |
| SCHEMBL12955388 | 0.80 | LMNA (0.72) | PARP1ARLMNACYP3A4CYP2C9 | |
| SCHEMBL3635493 | 0.80 | LMNA (0.56) | PARP1ARLMNACYP3A4CYP2C9 | |
| SCHEMBL13265573 | 0.78 | PARP1 (0.71) | PARP1ARLMNACYP3A4CYP2C9 | |
| SCHEMBL863462 | 0.78 | AR (1.00) | PARP1ARLMNACYP3A4CYP2C9 | |
| SCHEMBL3387433 | 0.78 | PARP1 (0.70) | PARP1ARLMNACYP3A4CYP2C9 | |
| SCHEMBL12798188 | 0.78 | PARP1 (0.70) | PARP1ARLMNACYP3A4CYP2C9 | |
| SCHEMBL4573019 | 0.78 | PARP1 (0.70) | PARP1ARLMNACYP3A4CYP2C9 | |
| SCHEMBL12955362 | 0.78 | PARP1 (0.70) | PARP1ARLMNACYP3A4CYP2C9 | |
| SCHEMBL29655200 | 0.78 | PARP1 (0.70) | PARP1ARLMNACYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7902193-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-7902193-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-7902193-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-20090069303-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| US-20090069303-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| US-20090069303-A1 | PHTHALAZINONE DERIVATIVES | MAYBRIDGE LIMITED (GB) | 2009-03-12 | — | — | US | disclosed |
| US-7470688-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2008-12-30 | — | — | US | disclosed |
| US-7470688-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2008-12-30 | — | — | US | disclosed |
| US-7470688-B2 | Phthalazinone derivatives | MAYBRIDGE LIMITED (GB) | 2008-12-30 | — | — | US | disclosed |
| EP-1948642-A1 | 4-HETEROARYMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | Kudos Pharmaceuticals Ltd (GB) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007045877-A1 | 4-HETEROARYMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
| WO-2007045877-A1 | 4-HETEROARYMETHYL SUBSTITUTED PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-04-26 | — | — | WO | disclosed |
| US-20070093489-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-04-26 | — | — | US | disclosed |
| US-20070093489-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-04-26 | — | — | US | disclosed |
| US-20070093489-A1 | PHTHALAZINONE DERIVATIVES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069303-A1 | PHTHALAZINONE DERIVATIVES | NR2C2, NR2E3, NR3C2 | PARP1 2875/4885AR 96/4885LMNA 1994/4885 |
| US-20070093489-A1 | PHTHALAZINONE DERIVATIVES | NR2C2, NR2E3, NR3C2 | PARP1 2388/4885AR 80/4885LMNA 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.